NCT00473005终止1 期
A Phase I Pilot Study of the Oral mTOR Inhibitor RAD001 in Combination With Capecitabine for Metastatic Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- Using three cohorts of patients with fixed dosing of capecitabine in combination with increasing doses of RAD001, the maximum tolerated doses and toxicities will be determined.
研究概览
简要总结
In order to improve the survival of metastatic breast patients, it is important to investigate the use of novel therapeutic agents combined with known active agents in the treatment of breast cancer. This is a phase I study evaluating the maximum tolerated doses and toxicities of RAD001 in combination with capecitabine for the treatment of metastatic breast cancer. RAD001 (INN: everolimus) is a novel macrolide, which is being developed as an antiproliferative drug with applications as an immunosuppressant and anticancer agent. Phase I trials in patients with solid tumors have shown that treatment with RAD001 is well-tolerated with a minimal side effect profile. Capecitabine (Xeloda, Roche) is an oral fluoropyrimidine that was approved in 1998 for the treatment of patients with metastatic breast cancer. The all-oral regimen of RAD001 with capecitabine is an attractive approach as the treatment of metastatic breast cancer has not yet proven to be curative. We also want to find out what possible benefit this combination of drugs might have on treating your cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients meeting all of the following criteria are eligible for this trial:
- •Histologically-confirmed metastatic breast cancer.
- •Measurable disease either by clinical exam or radiographs.
- •Patients must be fully recovered from acute toxicity of prior therapy.
- •Patients must not have received prior therapy with capecitabine.
- •Patients must not have received more than 3 prior chemotherapy regimens for metastatic breast cancer.
- •Patients must not be receiving concurrent endocrine therapy or immunotherapy.
- •Patients must have an expected survival of at least 3 months.
- •Patients should have ECOG performance status 0 or 1 (KPS 100-80%).
- •Patients should have adequate bone marrow, hepatic and renal function.
- •WBC >= 3000/mm^3,
- •ANC > 1500,
- •Hgb > 9 g/dL,
- •Platelets >= 100,000/mm^3,
- •total bilirubin<1 .5 mg/dL,
- •AST/ALT<2.5 x normal {<= 5x ULN in patients with liver metastases}
- •creatinine<2 mg/dL);
- •Fasting serum cholesterol ˜300 mg/dL OR ˜7.75 mmol/L AND fasting triglycerides ˜2.5 x ULN. (Note: In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication.)
- •Patients must be >18 years of age
- •Signed informed consent
排除标准
- •Patients meeting any of the following criteria will not be eligible for the trial:
- •Patients who have received other chemotherapy or endocrine therapy and not recovered from acute toxicity of previous therapy.
- •Patients who have received radiotherapy within 4 weeks prior to start of this trial.
- •Patients who have undergone major surgery within 2 weeks of study enrollment.
- •Patients with known evidence of brain metastases or leptomeningeal disease, , including patients who continue to require glucocorticoids for brain or leptomeningeal metastases..
- •Patients with a history of other cancers except curatively-treated carcinoma of the cervix in situ or non-melanomatous skin cancer. Patients with other cancers thought to be cured may be entered into the trial after discussion with and approval of the study chair.
- •Patients with an active serious infection or other serious underlying medical condition that would impair their ability to receive protocol treatment.
- •Patients with bone metastases as their only site of measurable disease.
- •Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent.
- •Pregnant or breast-feeding patients.
- •Patients not using adequate methods of birth control if still of child-bearing potential.
- •Patients who have received prior therapy with capecitabine.
- •Patients who have received more than 3 prior chemotherapy regimens for metastatic breast cancer.
- •Patients receiving other investigational therapy.
- •Patients who have received prior treatment with experimental therapy within 30 days prior to start of trial.
- •Patients who receive chronic systemic steroids or other immunosuppressive agents.
- •Patients with a known history of HIV.
- •Patients with impaired gastrointestinal function which may significantly decrease absorption of RAD001 and capecitabine.
- •Patients with an active, bleeding diathesis or receiving anti-vitamin K therapy. (except low dose coumadin)
- •Patients who have had prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus).
- •Patients who have any sever and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:
- •with uncontrolled diabetes mellitus,
- •uncontrolled hypertension,
- •severe malnutrition,
- •unstable angina, or congestive heart failure - New York Heart Association Class III or IV, ventricular arrhythmias, active ischemic heart disease,
- •myocardial infarction within 6 months, chronic liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis /
- •renal disease,
- •Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
- •Patients who have had prior bone marrow or stem cell transplant.
- •Patients receiving tube feeding or TPN, or who are 75% or less of their ideal body weight.
- •Patients with a caloric intake of less than 500 calories per day.
- •History of noncompliance to medical regimens
- •Patients unwilling to or unable to comply with the protocol
结局指标
主要结局
Using three cohorts of patients with fixed dosing of capecitabine in combination with increasing doses of RAD001, the maximum tolerated doses and toxicities will be determined.
时间窗: Measured at baseline and before every other cycle.
次要结局
- Tumor response(After every two cyclescycles (six weeks) of therapy for the first four cycles, then after every three cycles (nine weeks) for the remainder of the first year, then every four cycles (12 weeks).)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsAnaplastic AstrocytomaAnaplastic OligoastrocytomaAnaplastic OligodendrogliomaEstrogen Receptor NegativeEstrogen Receptor PositiveHormone-Resistant Prostate CancerMetastatic Prostate CarcinomaMetastatic Renal Cell CancerRecurrent Adult Brain NeoplasmRecurrent Bladder CarcinomaRecurrent Breast CarcinomaRecurrent Colorectal CarcinomaRecurrent Esophageal CarcinomaRecurrent Gastric CarcinomaRecurrent Hepatocellular CarcinomaRecurrent Lung CarcinomaRecurrent MelanomaRecurrent Ovarian CarcinomaRecurrent Prostate CarcinomaRecurrent Renal Cell CarcinomaGlioblastomaRecurrent Uterine Corpus CarcinomaResectable Hepatocellular CarcinomaStage IA Breast CancerStage IA Ovarian CancerStage IA Uterine Corpus CancerStage IB Breast CancerStage IB Ovarian CancerStage IB Uterine Corpus CancerStage IC Ovarian CancerStage II Uterine Corpus CancerStage IIA Breast CancerStage IIA Lung CarcinomaStage IIA Ovarian CancerStage IIB Breast CancerStage IIB Esophageal CancerStage IIB Lung CarcinomaStage IIB Ovarian CancerStage IIB Skin MelanomaStage IIC Ovarian CancerStage IIC Skin MelanomaStage IIIA Breast CancerStage IIIA Esophageal CancerStage IIIA Lung CarcinomaStage IIIA Ovarian CancerStage IIIA Skin MelanomaStage IIIA Uterine Corpus CancerStage IIIB Breast CancerStage IIIB Esophageal CancerStage IIIB Ovarian CancerStage IIIB Skin MelanomaStage IIIB Uterine Corpus CancerStage IIIC Breast CancerStage IIIC Esophageal CancerStage IIIC Ovarian CancerStage IIIC Skin MelanomaStage IIIC Uterine Corpus CancerStage IV Bladder Urothelial CarcinomaStage IV Esophageal CancerStage IV Ovarian CancerStage IV Prostate CancerStage IV Skin MelanomaStage IVA Uterine Corpus CancerStage IVB Uterine Corpus CancerSarcomaNCT01522820Roswell Park Cancer Institute18
终止
2 期
Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers SyndromePeutz-Jeghers SyndromeNCT00811590University of Utah3
终止
1 期
Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer PatientsAdvanced CancersNCT00877773M.D. Anderson Cancer Center44
已完成
2 期
Study of RAD001 in Adenoid Cystic CarcinomaAdenoid Cystic CarcinomaNCT01152840Seoul National University Hospital33
已完成
1 期
Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum CancerRectum CancerNCT00409994Maastricht Radiation Oncology44